Kiniksa Pharmaceuticals is a global biopharmaceutical company that finds and delivers novel treatments for patients with significant unmet need. We focus on cultivating a highly skilled and passionate team determined to deliver the promise of transformative therapies to patients who need them most. We are focused on building a better future for patients by developing a portfolio of differentiated and transformational therapeutics for patients with serious and life-threatening diseases.
In March of 2021, Kiniksa received FDA approval for ARCALYST® (rilonacept). Please visit booth #3225 at ACC 2022 or arcalystbooth.com/acc for more information.